SOLV · Full Picture

Solventum Corp — the full picture

Earnings window · 2026-07-15 to 2026-08-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

1. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 87
   -31.7% revenue; 3 sources (news, press_release, sec_filing); 6 forward row(s); quote_verified
   On September 1, 2025, Solventum completed the sale of its Purification and Filtration business to Thermo Fisher Scientific Inc., and the cash consideration paid at closing was approximately $4 billion.
2. Segment Revenue Performance · Revenue growth & mixPriority 86
   +84.5% revenue (realized); 3 sources (news, press_release, sec_filing); structured_verified
   Columbus McKinnon increased revenue by 125.3% year over year.
3. Market Demand Trends · Demand, orders & backlogPriority 78
   -0.0% net_income; 3 sources (news, press_release, sec_filing); 2 forward row(s); structured_verified
   The Solventum Foundation announced a $350,000 grant to America’s ToothFairy to expand access for more than 100,000 children and caregivers in underserved communities over the next year
4. Operating Expense Trends · Operating expenses (SG&A)Priority 74
   -20.5% operating_income (realized); 2 sources (press_release, sec_filing); structured_verified
   Selling, general and administrative (SG&A) expenses for Q2 2026: $927 million, a 20.1% increase year-over-year
5. Headcount / Restructuring · Restructuring & impairmentPriority 72
   -5.0% operating_income; 2 sources (press_release, sec_filing); 1 forward row(s); quote_verified
   In 2026 the Company's annual stock grant included 1.3 million RSUs with a weighted average grant date fair value of $70.78 and 0.5 million PSUs with a weighted average grant date fair value of $73.28.
6. Geographic Revenue Commentary · Geographic mixPriority 68
   +9.2% revenue (realized); 2 sources (press_release, sec_filing); structured_verified
   United States net sales for the three months ended June 30, 2026 were $1,313 million, representing 59.4% of worldwide sales for the quarter.
7. Guidance / Outlook · Guidance & outlookPriority 63
   +2.3% revenue; 2 sources (news, press_release); 6 forward row(s); quote_verified
   Full-year 2026 guidance: increased free cash flow range to $200 million to $300 million (from prior estimate of ~$200M)
8. Property Investment Increase · UnclassifiedPriority 61
   quote_verified
   As of June 30, 2026, the Company had right-of-use assets of approximately $__ million and related finance lease liability of approximately $__ million related to the Eagan office finance lease (amounts redacted).
9. Gross Margin Drivers · Gross marginPriority 60
   +5.4% operating_income (realized); 2 sources (press_release, sec_filing); quote_verified
   The Company recognized a pre-tax benefit of $120 million to cost of product within the condensed consolidated financial statements as of June 30, 2026 related to the accepted CBP refund requests.
10. Interest Rate and Refinancing Exposure · Interest ratesPriority 60
    quote_verified
    Aggregate principal amount of Senior Notes outstanding: $5.0 billion with maturities ranging from 2027 through 2064.
11. Liquidity and Debt Position · Liquidity & cash positionPriority 60
    +2.8% cash (realized); 2 sources (press_release, sec_filing); structured_verified
    Cash and cash equivalents at June 30, 2026: $403 million (down from $878 million at December 31, 2025)
12. Capital Return Program · Buybacks & dividendsPriority 56
    -2.5% cash (realized); 2 sources (press_release, sec_filing); structured_verified
    In November 2025, Solventum's Board of Directors approved a share repurchase program authorizing the Company to purchase up to $1 billion of the Company's outstanding common stock.

Threads by pillar

Revenue & Demand Priority 94 · 5 threads

• Segment Revenue PerformancePriority 86 · News, Release, Filing
• Market Demand TrendsPriority 78 · News, Release, Filing
• Geographic Revenue CommentaryPriority 68 · Release, Filing
• Products and TechnologyPriority 39 · Release, Filing
• Customer DynamicsPriority 27 · Release

Costs & Margins Priority 87 · 5 threads

• Operating Expense TrendsPriority 74 · Release, Filing
• Headcount / RestructuringPriority 72 · Release, Filing
• Gross Margin DriversPriority 60 · Release, Filing
• Supply Chain ConstraintsPriority 37 · News, Filing
• Net Income and ProfitabilityPriority 31 · News

Capital & Balance Sheet Priority 81 · 6 threads

• Liquidity and Debt PositionPriority 60 · Release, Filing
• Capital Return ProgramPriority 56 · Release, Filing
• Liquidity and Debt PositionPriority 50 · Filing
• Operating Cash Flow TrendsPriority 38 · Release, Filing
• Income Tax Rate ChangesPriority 38 · Release, Filing
• Capital ExpendituresPriority 32 · Release

Strategy & Portfolio Priority 87 · 1 thread

• Acquisition / Partnership / DivestiturePriority 87 · News, Release, Filing

Legal, Regulatory & Policy Priority 63 · 4 threads

• Litigation and Legal RiskPriority 48 · Release
• Product Liability LawsuitPriority 42 · Filing
• Trade Policy and TariffsPriority 41 · Filing
• Supply Chain Tariff ImpactPriority 20 · Release

Guidance & Outlook Priority 63 · 1 thread

• Guidance / OutlookPriority 63 · News, Release

Macro & Market Conditions Priority 69 · 3 threads

• Interest Rate and Refinancing ExposurePriority 60 · Filing
• FX / Currency HeadwindsPriority 56 · Filing
• Competition and Pricing PressurePriority 21 · News

Unclassified Priority 68 · 3 threads

• Property Investment IncreasePriority 61 · Filing
• Operating Margin DriversPriority 53 · Release
• Product Portfolio RationalizationPriority 30 · Filing

Expected impact by metric